title: A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis.
abstract: Despite the recent advances in drug research, finding a safe, effective, and easy to use chemotherapy for human African trypanosomiasis (HAT) remains a challenging task. The four current anti-trypanosomiasis drugs have major disadvantages that limit more widespread use of these drugs in the endemic regions of sub-Saharan Africa. Pentamidine and suramin are limited by their effectiveness against the only first stage of Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, respectively. In addition, melarsoprol and eflornithine (two second stage drugs) each have disadvantages of their own. The former is toxic and has increasing treatment failures while the latter is expensive, laborious to administer, and lacks efficacy against T. b. rhodesiense. Furthermore, melarsoprol's toxicity and decreasing efficacy are glaring problems and phasing out the drug as a frontline treatment against T. b. gambiense is now possible with the emergence of competent, safe combination chemotherapies such as nifurtimox-eflornithine combination treatment (NECT). The future of eflornithine, on the other hand, is more promising. The drug is useful in the context of combination chemotherapy and potential orally administered analogues. Due to the limits of monotherapies, greater emphasis should be placed on the research and development of combination chemotherapies, based on the successful clinical tests with NECT and its current use as a frontline anti-trypanosomiasis treatment. This review discussed the current and future chemotherapy strategies for the treatment of HAT.
authors.affiliation: University of Massachusetts, Boston, MA, USA. pbabokhov@gmail.com
authors.forename: Peter
authors.initials: P
authors.lastname: Babokhov
authors.forename: Adekunle O
authors.initials: AO
authors.lastname: Sanyaolu
authors.forename: Wellington A
authors.initials: WA
authors.lastname: Oyibo
authors.forename: Adetayo F
authors.initials: AF
authors.lastname: Fagbenro-Beyioku
authors.forename: Nnaemeka C
authors.initials: NC
authors.lastname: Iriemenam
mesh_terms: D000349:Africa / Q000453:epidemiology; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D004358:Drug Therapy / Q000379:methods; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D014347:Trypanosoma brucei gambiense / Q000187:drug effects; D016833:Trypanosoma brucei rhodesiense / Q000187:drug effects; D014353:Trypanosomiasis, African / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000981:Antiprotozoal Agents
references.citation: PLoS Negl Trop Dis. 2012 Aug;6(8):e1695
references.pmid: 22970329
references.citation: PLoS Negl Trop Dis. 2007 Nov 07;1(2):e64
references.pmid: 18060083
references.citation: BMJ. 2008 Mar 29;336(7646):705-8
references.pmid: 18321960
references.citation: J Antimicrob Chemother. 2009 Jun;63(6):1293-5
references.pmid: 19336455
references.citation: PLoS Biol. 2008 Jul 29;6(7):e185
references.pmid: 18666832
references.citation: Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8
references.pmid: 21911566
references.citation: PLoS Negl Trop Dis. 2010 May 04;4(5):e678
references.pmid: 20454560
references.citation: Future Med Chem. 2011 Aug;3(10):1259-78
references.pmid: 21859301
references.citation: PLoS Negl Trop Dis. 2011 Sep;5(9):e1308
references.pmid: 21909447
references.citation: Br J Pharmacol. 2007 Dec;152(8):1155-71
references.pmid: 17618313
references.citation: PLoS Negl Trop Dis. 2009 Aug 04;3(8):e495
references.pmid: 19652702
references.citation: Clin Infect Dis. 2007 Dec 1;45(11):1443-5
references.pmid: 17990226
references.citation: Antimicrob Agents Chemother. 2009 Oct;53(10):4185-92
references.pmid: 19620327
references.citation: Mini Rev Med Chem. 2009 Jun;9(6):674-86
references.pmid: 19519493
references.citation: Antimicrob Agents Chemother. 2009 Jan;53(1):123-8
references.pmid: 18824603
references.citation: J Clin Invest. 2004 Feb;113(4):496-504
references.pmid: 14966556
references.citation: J Neurochem. 2008 Nov;107(4):1136-46
references.pmid: 18823367
references.citation: Mutat Res. 2004 Jun 13;560(2):147-58
references.pmid: 15157652
references.citation: Parasitol Int. 2007 Dec;56(4):321-4
references.pmid: 17643344
references.citation: Clin Infect Dis. 2007 Dec 1;45(11):1435-42
references.pmid: 17990225
references.citation: Lancet. 2010 Jan 9;375(9709):148-59
references.pmid: 19833383
references.citation: J Pharmacol Exp Ther. 2009 Jun;329(3):967-77
references.pmid: 19261919
references.citation: Parasit Vectors. 2010 Mar 10;3(1):15
references.pmid: 20219092
references.citation: J Clin Invest. 2008 Apr;118(4):1301-10
references.pmid: 18382742
references.citation: Antimicrob Agents Chemother. 2007 Sep;51(9):3136-46
references.pmid: 17576845
references.citation: Trans R Soc Trop Med Hyg. 1996 Mar-Apr;90(2):183-6
references.pmid: 8761585
references.citation: Trans R Soc Trop Med Hyg. 2009 Mar;103(3):280-90
references.pmid: 18947846
references.citation: Br Med Bull. 2012;104:175-96
references.pmid: 23137768
references.citation: Neuropathol Appl Neurobiol. 1992 Dec;18(6):619-25
references.pmid: 1488091
references.citation: Future Microbiol. 2011 Sep;6(9):1037-47
references.pmid: 21958143
references.citation: Int J Health Geogr. 2010 Nov 01;9:57
references.pmid: 21040555
references.citation: Mol Pharmacol. 2001 Mar;59(3):586-92
references.pmid: 11179454
references.citation: J Neuroimmunol. 1999 Dec;100(1-2):36-41
references.pmid: 10695713
references.citation: J Infect Dis. 2005 Jun 1;191(11):1922-31
references.pmid: 15871127
references.citation: PLoS Negl Trop Dis. 2010 May 25;4(5):e720
references.pmid: 20520803
references.citation: Fundam Clin Pharmacol. 2003 Apr;17(2):171-81
references.pmid: 12667227
references.citation: Confl Health. 2011 May 26;5:7
references.pmid: 21615932
references.citation: PLoS Clin Trials. 2006 Dec 08;1(8):e39
references.pmid: 17160135
references.citation: Cochrane Database Syst Rev. 2010 Aug 04;(8):CD006201
references.pmid: 20687080
references.citation: Trends Parasitol. 2013 Mar;29(3):110-8
references.pmid: 23375541
references.citation: J Travel Med. 2012 Jan-Feb;19(1):44-53
references.pmid: 22221811
references.citation: Curr Opin Infect Dis. 2010 Dec;23(6):603-8
references.pmid: 20844428
references.citation: Microbes Infect. 2001 Jul;3(9):763-70
references.pmid: 11489425
references.citation: J Infect Dis. 2007 Feb 1;195(3):322-9
references.pmid: 17205469
references.citation: PLoS Negl Trop Dis. 2011 Feb 22;5(2):e1007
references.pmid: 21364972
references.citation: J Biol Chem. 2011 Apr 15;286(15):13088-95
references.pmid: 21345801
references.citation: J Biomed Biotechnol. 2010;2010:389153
references.pmid: 20182644
references.citation: Acta Trop. 2005 Mar;93(3):311-6
references.pmid: 15715983
references.citation: Parasitology. 2012 Jun;139(7):842-6
references.pmid: 22309684
references.citation: Lancet. 2003 Nov 1;362(9394):1469-80
references.pmid: 14602444
references.citation: PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923
references.pmid: 21200426
references.citation: Eur J Med Chem. 2011 May;46(5):1524-35
references.pmid: 21353728